The Massachusetts Life Sciences Center, in charge of administering the state’s newly-enacted $1 billion, 10-year program to boost the biotech industry, announced the members of its board of directors today and, in one of its first actions, voted to approve $7 million in grants. The seven-member board includes Joshua Boger, CEO of Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]), Peter Slavin, president of Massachusetts General Hospital, and Jack Wilson, president of the University of Massachusetts. The board voted to approve almost $7 million for grants that will be used to recruit and retain top scientific talent at universities in the state, and spur new research, according to a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
